Edesa Biotech Wins FDA Clearance for Phase 2 Vitiligo Study

FDA cleared Edesa Biotech's IND application for a Phase 2 vitiligo study of EB06, enabling expansion to U.S. sites. U.S. enrollment is expected to begin in the first quarter of 2027; topline results are anticipated in the fourth quarter of 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via (Ref. ID: 202610150915PRIMZONEFULLFEED9846150) on October 15, 2026, and is solely responsible for the information contained therein. (C)